Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unity Biotechnology Inc (NQ: UBX )

2.590 +0.120 (+4.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,798
Open 2.480
Bid (Size) 2.480 (2)
Ask (Size) 2.600 (6)
Prev. Close 2.470
Today's Range 2.460 - 2.590
52wk Range 1.461 - 5.720
Shares Outstanding 14,601,258
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Unity Biotechnology
Via Benzinga
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire

Performance

YTD
-12.50%
-12.50%
1 Month
+5.71%
+5.71%
3 Month
-21.28%
-21.28%
6 Month
-35.41%
-35.41%
1 Year
-42.16%
-42.16%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
Via Benzinga
The Latest Analyst Ratings for Unity Biotechnology
Via Benzinga
Where Unity Biotechnology Stands With Analysts
Via Benzinga
Recap: Unity Biotechnology Q1 Earnings
Via Benzinga
Where Unity Biotechnology Stands With Analysts
Via Benzinga
Expert Ratings for Unity Biotechnology
Via Benzinga
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
From Unity Biotechnology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
Via Benzinga
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
Via Benzinga
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
From Unity Biotechnology, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Nasdaq Edges Lower; Unity Biotechnology Shares Plummet
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
Via InvestorPlace
Gold Drops Over 1%; First Citizens BancShares Shares Spike Higher
Via Benzinga
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.